Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 22 05 2018
accepted: 13 09 2018
pubmed: 7 12 2018
medline: 16 4 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

There is an increasing interest in local tumor ablative treatment modalities that induce immunogenic cell death and the generation of antitumor immune responses. We report six recurrent glioblastoma patients who were treated with intracavitary thermotherapy after coating the resection cavity wall with superparamagnetic iron oxide nanoparticles ("NanoPaste" technique). Patients underwent six 1-h hyperthermia sessions in an alternating magnetic field and, if possible, received concurrent fractionated radiotherapy at a dose of 39.6 Gy. There were no major side effects during active treatment. However, after 2-5 months, patients developed increasing clinical symptoms. CT scans showed tumor flare reactions with prominent edema around nanoparticle deposits. Patients were treated with dexamethasone and, if necessary, underwent re-surgery to remove nanoparticles. Histopathology revealed sustained necrosis directly adjacent to aggregated nanoparticles without evidence for tumor activity. Immunohistochemistry showed upregulation of Caspase-3 and heat shock protein 70, prominent infiltration of macrophages with ingested nanoparticles and CD3 Intracavitary thermotherapy combined with radiotherapy can induce a prominent inflammatory reaction around the resection cavity which might trigger potent antitumor immune responses possibly leading to long-term stabilization of recurrent GBM patients. These results warrant further investigations in a prospective phase-I trial.

Sections du résumé

BACKGROUND BACKGROUND
There is an increasing interest in local tumor ablative treatment modalities that induce immunogenic cell death and the generation of antitumor immune responses.
METHODS METHODS
We report six recurrent glioblastoma patients who were treated with intracavitary thermotherapy after coating the resection cavity wall with superparamagnetic iron oxide nanoparticles ("NanoPaste" technique). Patients underwent six 1-h hyperthermia sessions in an alternating magnetic field and, if possible, received concurrent fractionated radiotherapy at a dose of 39.6 Gy.
RESULTS RESULTS
There were no major side effects during active treatment. However, after 2-5 months, patients developed increasing clinical symptoms. CT scans showed tumor flare reactions with prominent edema around nanoparticle deposits. Patients were treated with dexamethasone and, if necessary, underwent re-surgery to remove nanoparticles. Histopathology revealed sustained necrosis directly adjacent to aggregated nanoparticles without evidence for tumor activity. Immunohistochemistry showed upregulation of Caspase-3 and heat shock protein 70, prominent infiltration of macrophages with ingested nanoparticles and CD3
CONCLUSION CONCLUSIONS
Intracavitary thermotherapy combined with radiotherapy can induce a prominent inflammatory reaction around the resection cavity which might trigger potent antitumor immune responses possibly leading to long-term stabilization of recurrent GBM patients. These results warrant further investigations in a prospective phase-I trial.

Identifiants

pubmed: 30506500
doi: 10.1007/s11060-018-03005-x
pii: 10.1007/s11060-018-03005-x
pmc: PMC6341053
doi:

Substances chimiques

Ferric Compounds 0
Magnetite Nanoparticles 0
ferric oxide 1K09F3G675

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-94

Références

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41
pubmed: 10613305
Lancet. 2000 Apr 1;355(9210):1119-25
pubmed: 10791373
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
Cancer Immunol Immunother. 2003 Feb;52(2):80-8
pubmed: 12594571
Cancer Sci. 2003 Mar;94(3):308-13
pubmed: 12824927
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Clin Cancer Res. 2004 Jun 1;10(11):3699-707
pubmed: 15173076
J Endourol. 2004 Jun;18(5):495-500
pubmed: 15253831
Med Phys. 2004 Jun;31(6):1444-51
pubmed: 15259647
Stud Health Technol Inform. 2002;85:586-92
pubmed: 15458157
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):431-6
pubmed: 15625114
Prostate. 2005 Aug 1;64(3):283-92
pubmed: 15726645
Int J Cancer. 2005 Sep 10;116(4):624-33
pubmed: 15825167
Prostate. 2006 Jan 1;66(1):97-104
pubmed: 16114060
Cancer Immunol Immunother. 2006 Mar;55(3):320-8
pubmed: 16133113
J Neurooncol. 2005 Sep;74(2):167-71
pubmed: 16193388
J Neurooncol. 2006 May;78(1):7-14
pubmed: 16314937
Int J Hyperthermia. 2006 Jun;22(4):319-25
pubmed: 16754352
J Neurooncol. 2007 Jan;81(1):53-60
pubmed: 16773216
Int J Cancer. 2007 Jul 1;121(1):95-105
pubmed: 17315190
Radiat Oncol. 2007 Jul 14;2:26
pubmed: 17629934
J Neurooncol. 2008 Sep;89(2):205-10
pubmed: 18461281
Int J Hyperthermia. 2008 Sep;24(6):467-74
pubmed: 18608593
Biomaterials. 2009 Jan;30(1):52-7
pubmed: 18848723
Neuro Oncol. 2009 Aug;11(4):394-402
pubmed: 19028999
Biochem Cell Biol. 2008 Dec;86(6):521-38
pubmed: 19088800
Brain Pathol. 2009 Oct;19(4):674-93
pubmed: 19744040
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
J Neurooncol. 2011 Jun;103(2):317-24
pubmed: 20845061
Nanomedicine (Lond). 2013 Jun;8(6):891-902
pubmed: 23066648
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Radiat Oncol. 2014 Mar 30;9(1):89
pubmed: 24678590
Eur Surg Res. 2014;53(1-4):37-42
pubmed: 25059972
Front Immunol. 2015 Apr 15;6:162
pubmed: 25926832
Neuro Oncol. 2016 Jun;18(6):807-18
pubmed: 26578623
Radiother Oncol. 2016 Jan;118(1):35-42
pubmed: 26777122
JCI Insight. 2016;1(2):
pubmed: 26973881
Front Immunol. 2016 Apr 29;7:171
pubmed: 27199993
Anticancer Res. 2016 Oct;36(10):4985-4995
pubmed: 27798857
Medicine (Baltimore). 2017 Oct;96(43):e8293
pubmed: 29068998
Radiat Oncol. 2017 Dec 01;12(1):194
pubmed: 29195507
World Neurosurg. 2018 Jul;115:453-459.e3
pubmed: 29654958
Radiology. 1977 May;123(2):463-74
pubmed: 322205
Int J Hyperthermia. 1996 Nov-Dec;12(6):705-22
pubmed: 8950152
Int J Hyperthermia. 1997 Nov-Dec;13(6):587-605
pubmed: 9421741
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95
pubmed: 9457811
Jpn J Cancer Res. 1998 Jul;89(7):775-82
pubmed: 9738985

Auteurs

Oliver Grauer (O)

Department of Neurology, University Hospital of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. oliver.grauer@ukmuenster.de.

Mohammed Jaber (M)

Department of Neurosurgery, University Hospital of Münster, Münster, Germany.

Katharina Hess (K)

Institute of Neuropathology, University Hospital of Münster, Münster, Germany.

Matthias Weckesser (M)

Department of Nuclear Medicine, University Hospital of Münster, Münster, Germany.

Wolfram Schwindt (W)

Institute of Radiology, University Hospital of Münster, Münster, Germany.

Stephan Maring (S)

Department of Radiation Oncology, University Hospital of Münster, Münster, Germany.

Johannes Wölfer (J)

Department of Neurosurgery, University Hospital of Münster, Münster, Germany.
Competence Center for Neurosurgery, Hufeland Klinikum GmbH, Langensalzaer Landstraße 1, 99974, Mühlhausen, Germany.

Walter Stummer (W)

Department of Neurosurgery, University Hospital of Münster, Münster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH